Moderna’s market value has fallen by more than 90% — $185 billion, or a full Sony — from its 2021 peak to around $10 billion ...

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects ...

It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal government.

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and ...

Has BridgeBio's business model worked? How are executives at Moderna dealing with the company's slump? Find out on the new episode of "The Readout LOUD." ...

Moderna is backing the American Lung Association’s (ALA’s) call for people with lung diseases to get vaccinated for the ...

A social media giant faltered on Thursday, Oct. 30, 2025, as a tax event weighed on its results, while a biotech name benefitted from reports of talks with a major pharma player.

Jodi: That was Mike Katchen, the CEO of Wealthsimple, and my little brother. The New Work is produced by the HRPA and the ...

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...